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Abstract
Tumor-infiltrating dendritic cells are often ineffective at presenting tumor-derived antigen in vivo, a defect usually ascribed
to the suppressive tumor environment. We investigated the effects of depleting CD4
+CD25
+ ‘‘natural’’ regulatory T cells
(Treg) on the frequency, phenotype and function of total dendritic cell populations in B16.OVA tumors and in tumor-
draining lymph nodes. Intraperitoneal injection of the anti-CD25 monoclonal antibody PC61 reduced Treg frequency in
blood and tumors, but did not affect the frequency of tumor-infiltrating dendritic cells, or their expression of CD40, CD86
and MHCII. Tumor-infiltrating dendritic cells from PC61-treated or untreated mice induced the proliferation of allogeneic T
cells in vitro, but could not induce proliferation of OVA-specific OTI and OTII T cells unless specific peptide antigen was
added in culture. Some proliferation of naı ¨ve, OVA-specific OTI T cells, but not OTII T cells, was observed in the tumor-
draining LN of mice carrying B16.OVA tumors, however, this was not improved by PC61 treatment. Experiments using
RAG1
2/2 hosts adoptively transferred with OTI and CD25-depleted OTII cells also failed to show improved OTI and OTII T
cell proliferation in vivo compared to C57BL/6 hosts. We conclude that the defective presentation of B16.OVA tumor antigen
by tumor-infiltrating dendritic cells and in the tumor-draining lymph node is not due to the presence of ‘‘natural’’
CD4
+CD25
+ Treg.
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Introduction
The presence of dendritic cells (DC) in numerous human [1] and
murine tumors [2,3] is well established. The role of these tumor-
infiltrating DC (TIDC) in the tumor-specific immune response, and
their value as indicators of disease progression, are, however,
unclear [4,5]. A number of studies have shown that TIDC have
poor tumor antigen presenting function in vitro and in vivo [3,6–13].
Tumorsrepresentanimmunosuppressiveenvironmentcontaininga
range of inhibitory mechanisms such as decreased inflammatory
cytokines, increased anti-inflammatory cytokines [14,15] and
increased Treg infiltration [16,17], which are likely to affect the
function of local T cells [18] as well as DC [7].
The term ‘‘regulatory T cells’’ (Treg) refers to a range of cells
which express distinct phenotypes but share a common suppressive
function [19]. Among these suppressive populations, CD4
+CD25
+
‘‘natural’’ Treg (from now on referred to as ‘‘Treg’’) are prominent
due to their essential role in the maintenance of self-tolerance. Treg
require expression of the transcriptionfactor Foxp3 for their normal
development in the thymus, and are thought to require antigen
specific activation by DC in order to acquire effector function in the
periphery [20,21]. Mice in which Treg function is defective develop
severe autoimmunity that can be prevented by the transfer of
CD4
+CD25
+ T cells [22,23]. Treg suppress T cell proliferation and
degranulation, inhibit CTL function, and may cause T cell death
through production of the anti-inflammatory molecules adenosine,
transforming growth factor (TGF)-b and interleukin (IL)-10, and
inhibition of IL-2 transcription in T cells (reviewed in [21]). It has
further been proposed that Treg may cause cytokine deprivation-
induced apoptosis of target T cells, or even directly kill target cells
using granzyme B and perforin [21,24,25]. Treg have been shown
to inhibit productionof inflammatorycytokines such as Interferon-c
[26], Tumor Necrosis Factor-a [27] and the cytolytic granule
proteins perforin and granzymes [28].
In addition to their suppressive effect on T cells, Treg may also
suppress macrophages, natural killer (NK) cells, B cells [21] as well
as DC. Studies in non-obese diabetic mice have shown that Treg
can inhibit the expression of the DC activation markers CD40,
CD80, CD86 and MHCII, both in vitro and in vivo [21,29,30], and
interact directly with DC during immune responses [31],
decreasing the interaction time between effector T cells and DC
[32]. A number of studies have also shown that Treg indirectly
control DC homeostasis in vivo [23,33,34]. In tumor bearing mice,
Treg have been shown to induce DC death in the lymph node
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17515(LN) [35], but little information is available on whether Treg may
affect the number, phenotype or function of DC within the tumor
context. Effects on DC antigen uptake and/or function might
result in diminished T cell activation and effector differentiation
within the tumor [36]. Effects on DC migration and/or function
might also lead to decreased antigen presentation in the draining
LN. In this paper we use a B16.OVA melanoma model to
investigate and report the effects of Treg depletion on the antigen
presenting function of TIDC in vitro and in vivo.
Materials and Methods
Ethics statement
All experimental procedures were approved by the Victoria
University Animal Ethics Committee (permits 2004R6M and
2007R4M) and carried out according to Institutional guidelines.
Mice
All mice were bred at the Malaghan Institute of Medical
Research Biomedical Research Unit. C57BL/6J mice were
originally from Jackson Laboratories, Bar Harbor, ME, while
CD45-congenic B6.SJL-Ptprc
aPep3
b/BoyJArc (CD45.1) were from
the Animal Resource Centre, Canning Vale, Western Australia.
OTI and OTII mice expressing transgenic T cell receptors (TCR)
specific for K
b+OVA257–264 and I-A
b+OVA323–339, respectively,
were obtained with the permission of F. Carbone, Melbourne
University, Australia. Foxp3GFP mice [37] were obtained from
Prof. A. Rudensky, University of Washington, USA; hemizygous
males were used in all experiments. B6.129-Rag1
tm1Mom mice
(RAG1
2/2) were from the Walter and Eliza Hall Institute,
Melbourne, Australia. Mice were used when 6–8 weeks old and
gender-matched within experiments.
Media and reagents
Cells were cultured in Iscove’s Modified Dulbecco’s Medium
(IMDM) supplemented with 5% Fetal Bovine Serum (FCS),
100 U/ml penicillin, 100 mg/ml streptomycin and 50 mM2 -
mercapto-ethanol (all from Invitrogen, Auckland, NZ). Synthetic
peptides were from Mimotopes Pty Ltd (Clayton, Victoria,
Australia).
Antibodies and flow cytometry
Monoclonal antibodies specific for murine CD11c, MHCII,
F4/80, CD25 and CD3 were affinity-purified from hybridoma
culture supernatants using protein G-Sepharose (Pharmacia
Biotech, Uppsala, Sweden) and were left purified or conjugated
to various fluorophores. Fluorescent antibodies specific for CD45,
CD8a CD11b, CD11c, MHCII, CD86, CD40 and CD25 were
from BD-Pharmingen (San Diego, USA). Anti-CD45 and anti-
Foxp3 intracellular staining kits were from eBioscience (San Diego,
USA). All reagents were used according to manufacturer’s
instructions. Live cells were identified by FSC and SSC properties.
Treg depletion
Mice were given two intraperitoneal (i.p.) injections of 100 mg
purified PC61, 3 days apart [38]. Where applicable, tumor
inoculation was carried out one day following the last PC61
injection. Treg depletion was estimated by flow cytometry of tail
blood samples.
Isolation of T cells
LN from OTI or OTII mice were pressed through a 70 mm cell
strainer (BD Falcon, USA). CD8
+ T cells were positively selected
from OTI cell suspensions using anti-CD8a-MACS beads
(Miltenyi Biotec, Germany) and magnetic sorting. Effector CD4
+
T cells were first depleted of CD25
+ cells by incubation with anti-
CD25-PE followed by anti-PE MACS beads and negative
magnetic selection, followed by positive selection with anti-CD4-
MACS beads. OTI and OTII cell populations were routinely
.95% and ,80% pure, respectively.
Tumor experiments
The B16.OVA cell line [39] was kindly provided by Drs. Roslyn
Kemp and Dick Dutton, Trudeau Institute, USA, while B16.F1
was from ATCC, Manassas, VA, USA. Mice were injected
subcutaneously (s.c.) with 10
5 tumor cells into the flank, and tumor
growth was measured every 2 days using calipers. Tumors were
removed, weighed, dissociated using tweezers and digested with
0.4 mg/ml Liberase CI (Roche Applied Science, Mannheim,
Germany) and 0.1 mg/ml DNase I (Roche) for 30 min at 37uC.
Digestion was stopped with 10 mM EDTA for 5 min at 37uC and
suspensions pressed through 70 mm cell strainers.
Isolation and quantification of TIDC
Tumor cell suspensions were prepared, counted using trypan
blue, and the frequency of live cells that were CD45
+, CD11c
hi
was determined by flow cytometry. For sorting experiments,
leukocytes were enriched to ,20% using anti-CD45-PE, anti-PE
MACS beads, and magnetic selection. Cells were then incubated
with anti-CD11c and electronically sorted to obtain a population
that was .96% pure.
In vitro suppression assay
Tumor cell suspensions from Foxp3GFP mice were enriched for
CD4
+ cells using anti-CD4-MACS beads and magnetic selection.
Cells were then incubated with anti-CD45-PE, and GFP
+CD45
+
cells were electronically sorted to approximately 98%
CD45
+GFP
+. These Treg were cultured at differing ratios with a
constant number of DC (2.4610
3/well), CD4
+ CD25
2 effector T
cells (4610
4/well), and 1 mg/ml anti-CD3 for 3 days.
3H-
thymidine (1 mCi/ml, Amersham, Aylesbury, UK) was added
during the last 6 h of culture before harvesting on a Tomtec cell
harvester (Orange, CT, USA) and counting on a Betacounter
(Wallac, Turku, Finland) to determine the amount of proliferation.
In vitro proliferation assays
TIDC were sorted and titrated in duplicate into 96 well U
bottom plates containing 2610
5 purified OTI or OTII T cells in a
total volume of 200 mL. After 3 days, 1 mCi
3H-thymidine was
added to each well for 6 hours. Cells were harvested and counted
as above.
Carboxyfluorescein succinimidyl ester (CFSE) labeling
Single cell suspensions (5610
6 cells/ml) were incubated for
10 min at 37uC with 0.2 mM CFSE (Molecular Probes, Eugene,
Oregon). The reaction was stopped by adding one volume of FBS.
Cells were washed once with complete media and twice with PBS.
In vivo proliferation assays
B6.SJL mice were inoculated with tumor and 13 days later were
injected s.c. in the forearm with 2610
5 DC that were loaded with
1 uM OVA257–264 (SIINFEKL) or left untreated. One day later,
mice were injected i.v. with 1.5610
6 OTI and 1.5610
6 OTII T
cells labeled with CFSE. Tumor-draining and non-draining LN
were removed 3 days after T cell transfer, and analyzed for T cell
proliferation by flow cytometry.
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Tumor-derived CD25
+ Foxp3
+ Treg suppress T cell
proliferation in vitro and are depleted by PC61 treatment
To establish whether Treg were present in B16.OVA tumors,
we used Foxp3GFP mice where natural Treg can be easily
identified by Green Fluorescent Protein (GFP) expression (Figure
S1 and [37]). In B16.OVA tumors, ,14% of the CD4
+ T cell
population was Foxp3GFP
+, as opposed to the ,10% observed in
the tumor-draining and non-draining LN (Figure 1A and 1B), and
their frequency increased during tumor growth (Figure 1C). This
Foxp3GFP
+ population may also include ‘‘induced’’ Treg, but is
unlikely to include Tr1 cells which are Foxp3GFP
2 and CD25
2
[19].
In tumor-bearing mice, PC61 treatment routinely achieved a
40–70% depletion of the Foxp3GFP
+ population in blood, which
was maintained throughout the experiment (Figure S1A and
Figure 1D). The remaining Foxp3GFP
+ population was
essentially CD25
2 until the very final stages of tumor growth
(Figure S1B). The intratumoral Foxp3GFP
+ population was still
Figure 1. Tumor-infiltrating Foxp3
+ Treg are suppressive in vitro and affect tumor growth. Foxp3GFP mice were treated with PC61 or left
untreated, and injected with B16.OVA tumors s.c. Tissues were removed for analysis at different times after tumor challenge. (A) The frequencies of
Treg in tumors from non-depleted mice, or mice depleted of Treg by PC61 treatment, were determined by flow cytometry. Each panel refers to an
individual representative mouse. (B, C) Frequencies of Foxp3GFP
+ cells in different tissues (B) and in tumors of different sizes (C), determined as
shown in panel A. Each dot represents one mouse. Data are from 2 experiments, each with 4–5 mice per group, collected 14–17 days after tumor
inoculation. Average values are shown by a horizontal line, p values were calculated using one-way ANOVA. (D) Mice were treated with PC61 (solid
arrows) or left untreated, and injected with B16.OVA (arrow with broken line). Mice were bled over time to monitor the frequency of Foxp3GFP
+ Treg
within the peripheral CD4
+ population. Average 6 SEM for groups of 5 mice are shown. (E) CD4
+ Foxp3GFP
+ Treg were sorted from tumors and
titrated into wells containing constant numbers of purified CD4
+CD25
2 effector T cells, DC, and anti-CD3. Proliferation was measured 3 days later.
Bars represent average 6 range for duplicate samples. (F) C57BL/6 mice were treated with PC61 as in D or left untreated, and inoculated with tumor.
Average tumor sizes 6 SEM are shown. Results are from one of 4 repeat experiments that gave similar results. Values of p (where *,0.05 and
***,0.001) were calculated using a non-parametric one-way ANOVA with a Dunn’s post-test.
doi:10.1371/journal.pone.0017515.g001
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day 17 (Figure 1A and 1B). As also shown by others [21,40],
tumor derived Foxp3GFP
+ cells were able to suppress the
proliferation of conventional T cells in vitro (Figure 1E).
Treatment with PC61 in vivo resulted in a significant delay in
tumor growth, and by day 20 tumors in Treg-depleted mice
were only about one third of the size in the non-depleted group
(Figure 1F). Together, these data suggest that Treg are present
in B16.OVA tumors from an early stage, and may contribute to
their rapid growth.
Treg do not affect the frequency or phenotype of DC in
B16.OVA tumors and in draining LN
Since Treg are present at relatively high frequencies in both
tumor tissue and LN (Figure 1B), we hypothesized that one of their
targets for suppression would be resident DC. TIDC were
identified as CD45
+ and CD11c
hi, and comprised CD11b
hi and
CD11b
int subpopulations (Figure 2A). Both subpopulations
expressed CD40, CD86 and MHCII, although expression was
highest on CD11b
hi DC. In addition to the CD11c
hi subpopula-
tions, tumors also contained a population of cells expressing
Figure 2. Treg depletion does not affect the frequency or phenotype of TIDC and DC in LN. C57BL/6 mice were treated with PC61 or left
untreated, and injected with B16.OVA s.c. Tumors and LN were removed for analysis at different times after tumor challenge. (A) Gating strategy used
to identify TIDC (CD45
+, CD11c
hi, CD11b
hi/int) and assess expression of CD40, CD86 and MHCII. Fluorescence-minus-one controls (CD40) and isotype
controls (CD86 and MHCII) are shown as grey filled histograms, while empty histograms show marker expression. Percentages of cells expressing the
relevant markers are shown. (B) Frequencies of DC in tumors, expressed as % CD11c
hi cells in the CD45
+ population. Each dot corresponds to one
mouse. Data are from 3 experiments, each with 4–5 mice per group. (C) Numbers of DC per mg of tumor when tumors in both groups are of similar
size (200–300 mg). Bars show the average number of DC+SE from 2 experiments each with 3–4 mice per group. The average tumor size in the two
groups was similar. (D) Percentages of TIDC expressing the indicated maturation markers in Treg-depleted and non-depleted mice. Bars show the
average+SEM for a compilation of 3 independent experiments each with 5 mice per group. (E) Expression of maturation markers on DC in untreated
mice, and in Treg-depleted and non-depleted tumor-bearing mice. Both the tumor-draining and non-draining LN were examined. Averages+SEM
from 3 independent experiments each with 5 mice per group are shown.
doi:10.1371/journal.pone.0017515.g002
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represented only a small proportion of TIDC and were not
further examined.
As shown in Figure 1F, B16.OVA tumors grew more slowly in
Treg-depleted mice. To obtain tumors of similar size, Treg-
depleted and non-depleted mice were injected with tumor 1–2
days apart. When TIDC were compared between these two
groups, no difference could be observed in DC frequency, number
per milligram of tumor tissue, or phenotype (Figures 2B, 2C, 2D).
Results shown in Figures 2B, 2C, and 2D refer to CD11b
hi cells,
but similar results were obtained with the CD11b
int population
(data not shown). CD40, CD86 and MHCII were similarly
expressed in the TIDC from both treatment groups, both as
percentage of positive cells (Figure 2D) and as Mean Fluorescence
Intensity (MFI) in the total population (data not shown). The
relative frequencies of CD11b
hi and CD11b
int TIDC subpopula-
tions were also similar in untreated and Treg-depleted mice (data
not shown). Treg depletion did not affect the number or
maturation status of DC in the LN, nor was there a difference
in maturation status between DC in the draining and non-draining
LN, both when measured as percent positive cells or as MFI
(Figure 2E and data not shown). Thus, Treg depletion does not
appear to affect the numbers or phenotype of DC in the tumor, or
DC phenotype in the tumor-draining LN.
Treg depletion does not improve the ability of TIDC to
induce proliferation of tumor-specific T cells in vitro
CD45
+CD11c
+ cells, including both CD11b
hi and CD11b
int
DC subpopulations, were electronically sorted from tumor cell
suspensions to a high purity (.96%) and used to stimulate the
proliferation of OVA-specific CD4
+ OTII and CD8
+ OTI T cells
in vitro. To test the presentation of tumor antigen taken up by DC
within the tumor context, no further antigen was added to the
assay except in the positive controls. As previously reported [3], in
the absence of added antigen, sorted DC were unable to stimulate
proliferation of OVA-specific OTII cells (Figure 3A) and induced
only minimal proliferation of OVA-specific OTI cells (Figure 3B).
The low proliferation of OTI cells was not antigen-specific, as it
was observed even when DC were prepared from B16.F1 tumors
that do not express OVA [3]. Sorted DC were otherwise able to
present synthetic peptide to OTI and OTII cells [3], or added
OVA protein to OTII cells (data not shown), to induce
proliferation in vitro. When TIDC were prepared from the tumors
of Treg-depleted mice, no increase in the proliferation of OTI or
OTII cells was observed (Figure 3A and 3B).
Although TIDC were unable to present OVA taken up within
the tumor context, they appeared functional as they could
stimulate the proliferation of specific T cells in the presence of
peptide (Figure 3A and 3B), and proliferation of allogeneic BALB/
c T cells in vitro (Figure 3C). In both cases, Treg depletion did not
improve the response.
Treg depletion does not improve the proliferation of
tumor-specific OTI T cells in the tumor-draining LN
Since removing DC from the tumor environment might reverse
the effects of Treg on DC in situ, we also examined the
presentation of tumor-derived antigen using an in vivo assay.
Presentation of tumor antigen in the draining LN is thought to
reflect migration of DC from the tumor site, which is known to be
defective [1] but might improve if the frequency of Treg in the
tumor is decreased. Presentation in the LN may also reflect
transfer of antigen from migratory to resident DC [41], which
would bypass antigen presentation defects in tumor-derived DC.
Naı ¨ve, CFSE-labeled OTI T cells were transferred into Treg-
depleted or non-depleted tumor-bearing mice, and their prolifer-
ation in tumor-draining LN was compared 3 days later. A
representative dot plot of OTI proliferation in tumor-bearing mice
is shown in the top panel of Figure 4A. As a control, we used non
tumor-bearing mice immunized with DC+OVA257–264; a repre-
sentative dot plot of OTI proliferation in the LN draining the DC
injection site is shown in the lower panel of Figure 4A. Little OTI
T cell proliferation was observed in non tumor-bearing mice that
received DC not loaded with OVA257–264 (Figure 4B). A high level
of proliferation was detected in some of the tumor-bearing mice,
which was antigen-specific [3], but always lower in extent than the
proliferation observed in the positive controls (Figure 4A). This
proliferation was not increased in magnitude (Figure 4B) or
frequency (Figure 4C) by Treg depletion. Surprisingly, the
proportion of mice where T cells proliferated was even decreased
in Treg-depleted mice, however, this decrease was not statistically
significant (p=0.17 by a Fishers exact probability test) and further
experiments are required to establish the reproducibility of this
observation. High proliferation was observed in all mice injected
with OVA257–264-loaded DC, indicating that the transferred T
cells were functional and were not adversely affected by the
presence of tumor, or by PC61 treatment (Figure 4B).
Figure 3. Treg depletion does not increase the ability of TIDC to stimulate T cell proliferation ex vivo. C57BL/6 mice were treated with
PC61 or left untreated, and injected with B16.OVA s.c. After 14–17 days CD45
+ CD11c
hi TIDC were sorted and titrated in triplicate into cultures
containing (A) OTII T cells, (B) OTI T cells or (C) BALB/c allogeneic T cells. As a positive control, specific peptide antigen was loaded on 10
3 TIDC/well
before co-culture with T cells where indicated. Proliferation was measured 3 days later. Each panel shows one of 3 independent experiments that
gave similar results. Average 6 SEM are shown. p was calculated using a two-way ANOVA test with a Bonferroni post-test.
doi:10.1371/journal.pone.0017515.g003
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ation of CD4
+ OTII cells. As previously reported using both low
and highly immunogenic models, no CD4
+ OTII T cell
proliferation was detected in tumor-bearing mice [3,10]. Addi-
tional experiments in PC61-treated mice showed that proliferation
was not restored by Treg depletion (data not shown).
The proliferation of OTI T cells is not increased in the
tumor-draining LN of RAG1
2/2 compared to C57BL/6
mice
To determine whether the residual Treg population seen in
PC61-treated mice (Figures 1A and 1B) might be sufficient to affect
DC function in tumor-bearing mice, we examined tumor-specific T
cell proliferation in RAG1
2/2 mice, which lack all T cells including
Treg. TIDC were present in tumors from RAG1
2/2 mice at
frequencies similar to those in C57BL/6 tumors (Figure S2A) and
expressed similar, although slightly less mature, activation pheno-
types (Figure S2B). TIDC phenotype in RAG1
2/2 mice was not
significantly affected by the transfer of purified CD8
+ T cells or
CD4
+CD25
+ Treg one day before tumor inoculation (data not
shown).
To examine the effect of Treg on tumor-specific T cell
proliferation in vivo, C57BL/6 and RAG1
2/2 mice were
inoculated with either B16.OVA or OVA-negative B16.F1
tumors. Both tumors grew at a similar rate in the two strains
(Figure 5A) suggesting that in C57BL/6 hosts there was little
spontaneous T cell response to the B16 tumors. Tumor-bearing
mice received CFSE-labeled OTI and CD25-depleted OTII T
cells and OVA-specific proliferation was compared in the tumor-
draining (Figure 5B) and non-draining LN 3 days later. As shown
in Figure S3, the OTII populations contained low frequencies of
Foxp3
+ T cells that were further decreased by CD25 depletion;
about half of the remaining cells expressed the transgenic TCR
and were presumably OVA-specific.
It has been shown that in lymphopenic hosts OTI T cells
undergo 2–3 rounds of homeostatic proliferation in the absence of
antigen [42] therefore, to exclude homeostatic proliferation, only
OTI cells that had divided more than 3 times were considered.
This division was mostly antigen-specific, as it occurred in the LN
draining B16.OVA tumors but not in those draining B16.F1.
Specific OTI T cell proliferation was not increased in RAG1
2/2
mice compared to C57BL/6 (Figure 5C), suggesting that Treg
were not inhibiting OTI T cell division in C57BL/6 mice.
Similarly, little or no division of OTII T cells was observed in
C57BL/6 or RAG1
2/2 mice injected with either B16.OVA or
B16.F1 tumors (data not shown), again suggesting that lack of
division was not due to the presence of Treg in C57BL/6 mice.
Discussion
The recruitment of Treg to tumors is an early event in tumor
establishment [43]. The negative correlation observed between the
presence of Treg in tumors and survival outcome [44] suggests
that these Treg are probably assisting in the evasion of the immune
response. As also reported in other tumor models [17,40] we found
that even small B16.OVA melanoma tumors contained higher
frequencies of CD25
+ Foxp3
+ Treg than blood, and that tumor-
infiltrating Treg had suppressive activity in vitro. Somewhat
surprisingly, we also found that depletion of Treg appeared to
have no detectable effect on the frequency, phenotype or function
of TIDC. A partial but functionally relevant depletion via injection
of the anti-CD25 monoclonal antibody PC61, or a more profound
depletion by the use of RAG1
2/2 hosts, both failed to affect
TIDC phenotype. Similarly, defective proliferation of tumor-
specific CD4
+ and CD8
+ T cells in tumor-draining LN, which may
reflect presentation of tumor antigen by DC migrating from the
tumor to the LN, was not improved in these mice. Therefore,
CD4
+CD25
+ Treg appeared to have no effect on the presentation
of tumor antigen by DC in this tumor model, possibly suggesting
Figure 4. Treg depletion does not affect the proliferation of tumor-specific T cells in vivo. C57BL/6 mice were treated with PC61 or left
untreated, and injected with B16.OVA s.c. After 13–16 days each mouse was injected with 1.5610
6 naı ¨ve, CFSE-labeled OTI T cells. LN were removed 3
days later and OTI T cell proliferation was determined by flow cytometry. (A) Representative dot plots of proliferating OTI T cells in the draining LN of
tumor-bearing mice (top panel) or non tumor-bearing mice immunized with OVA257–264 -loaded DC (bottom panel). The percent divided cells is
shown. (B) Division of OTI T cells in LN draining the tumor or DC immunization site. Where both tumor and DC were given, the LN draining the
immunization site was examined. Horizontal lines show the average percentages of divided cells. The graph is representative of 4 independent
experiments with 5–10 mice per group per experiment. (C) Percentage of mice showing OTI T cell proliferation in the tumor-draining LN. The total
number of mice (n) in each group is shown. Data are compiled from 3 separate experiments; ns, not significant by a Fisher’s exact probability test.
doi:10.1371/journal.pone.0017515.g004
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treatment were involved.
It has been shown that Treg suppress the responses of many cell
types, using a variety of mechanisms including direct killing
[21,24,35]. Using the B16.OVA melanoma model, we found no
significant difference between the numbers, frequency or relative
proportions of TIDC populations in Treg-depleted and non-
depleted mice. The frequency and absolute number of DC in the
LN were also similar (data not shown). These observations fail to
support the possibility that in this tumor model CD4
+CD25
+ Treg
inhibit DC function by directly or indirectly affecting their
survival.
Experiments using both in vitro and in vivo models have shown
that, in the presence of Treg, DC express decreased levels of the
maturation markers CD40, CD80, CD86 and MHCII (reviewed
in [21]). The DC subpopulation/s that are involved in
presentation of tumor antigen in B16.OVA melanoma tumors
have not been precisely identified, however, in other tumor models
multiple DC subpopulations can present tumor antigen in the
draining LN [45]. On this basis, we chose to include in our
analysis all CD11c
hi DC subpopulations in these tissues. While DC
in B16.OVA tumors and LN appeared relatively mature, there
was no effect of Treg depletion on the proportion of TIDC
subpopulations, or on any of the DC activation markers tested.
Both TIDC and Treg localized mainly to the peripheral area of
B16 tumors and could often be found in close proximity to each
other (data not shown), suggesting that the two populations had
the potential to interact within the tumor context. Additional
experiments showed that Treg depletion also did not rescue or
enhance the ability of TIDC to stimulate the proliferation of
tumor-specific T cells in vitro, or the ability of DC in tumor-
draining LN to stimulate T cell proliferation in vivo. Taken
together, our results suggest that Treg had little or no effect on
TIDC in this tumor model.
Our inability to demonstrate an effect of PC61 treatment on
DC function could not be explained by incomplete Treg depletion,
as the same results were observed using a RAG1
2/2 model in
which Treg depletion was profound. Transfer of CD8
+ OTI and
CD25-depleted CD4
+ OTII T cells into RAG1
2/2 tumor-bearing
mice 3 days before analysis provided a model in which significant
conversion of CD4
+ T cells into Treg was unlikely to occur, but
CD4
+ T cells could provide help to DC thereby rescuing potential
defects in DC function due to lymphopenic conditions [46]. Even
in this situation, the proliferation of OTI or OTII cells was not
improved, suggesting the presentation of tumor antigen in the
draining LN was similar in RAG1
2/2 hosts and C57BL/6 mice.
It is conceivable that the effects of Treg on DC might have been
missed in our experiments, if these only occur early during tumor
development, at time points where the limited amount of tumor
tissue available makes the study of TIDC more difficult. We
believe that this is unlikely to be the case, as we and others have
shown that as the tumor increases in size, the frequency of Treg
Figure 5. The proliferation of tumor-specific OTI T cells in tumor-bearing C57BL/6 and RAG1
2/2 hosts is similar. C57BL/6 and RAG1
2/2
mice were injected with B16.OVA or B16.F1 s.c.. After 15 days each mouse was injected with 1.5610
6 naı ¨ve, CD8-enriched, CFSE-labeled OTI T cells
and 1.5610
6 naı ¨ve, CD25-depleted, CD4-enriched, CFSE-labeled OTII T cells. LN were removed 3 days later and T cell proliferation was determined by
flow cytometry. (A) Tumor size at the experimental endpoint (day 18); each dot corresponds to one mouse and the horizontal line shows the average
tumor size. (B) Gating strategy used to identify the donor OTI T cell population in the draining LN. Antigen-specific division was determined on the
basis of CFSE dilution as shown in the right-hand dot plots. (C) Antigen-specific OTI T cell division in the tumor-draining and non-draining LN of
C57BL/6 and RAG1
2/2 mice. Bars show the average percentage of cells that divided more than 3 times, +SEM. Data is from one experiment with 6–9
mice per group. p was calculated using two-way ANOVA with a Bonferroni post-test.
doi:10.1371/journal.pone.0017515.g005
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Under these increasingly hostile conditions, it is doubtful that
suppression could be spontaneously overcome, and any effects that
the Treg may have had on the DC at early timepoints are likely to
still be evident at later stages of tumor growth.
A recent paper used an OVA-expressing 3-methylcholanthrene
(MCA)-induced tumor to report that tumor antigen-specific Treg
could directly kill DC in the tumor draining LN [35]. A detailed
comparison of those findings with ours is not possible, as the
presence and localization of Treg and DC within tumors, and the
ability of tumor-derived DC to present OVA to T cells, were not
characterized [35]. The observation that Treg rapidly kill DC
presenting tumor antigen in the LN might suggest that DC in
MCA tumors do not come into contact with Treg, and can
therefore survive unaffected until they reach the LN. A differential
ability of TIDC from MCA or B16 tumors to present OVA
antigen in the context of MHCII, and induce activation of CD4
+
T cells and Treg, might also contribute to the different findings in
these studies.
It has been reported that antigen derived from normal tissues
can be presented to self-reactive CD4
+ T cells in the draining LN
and elicit a response [47,48]. In tumors this is not always the case,
and reports by other Authors and ourselves [3,49–51] suggest that
TIDC may be unable to induce productive activation of CD4
+ T
cells. A reduced ability of TIDC to activate conventional CD4
+ T
cells might also imply a reduced ability of these DC to activate
Treg, as suggested by experiments showing that in inflamed tissue
the same DC drive cytokine production by both CD4
+ Teff and
Treg [52]. If this is the case, the results reported in this study might
be explained by hypothesizing that Treg accumulate in the tumor,
but fail to recognize the appropriate ligands in the context of DC
to become activated to effector function. As it has been shown by
us (Figure 1F) and by other Authors [53] that Treg depletion
delays the growth of B16 tumors (Figure 1F), and improves the
anti-tumor efficacy of both prophylactic [38] and therapeutic [54]
DC immunotherapy, Treg must be suppressing anti-tumor
immune responses by mechanisms other than acting on DC. For
example, reports using intravital microscopy of mouse LN have
demonstrated that Treg can directly act on T cells to suppress
immune responses [55]. In our studies, Treg depletion did not
improve CD4
+ or CD8
+ T cell proliferation, implying that any
direct effect of Treg on T cells might have an impact on the quality
of the T cell response, rather than the quantity. The defective DC
function we and others observe in tumor-bearing mice [3,6,7,9–
12] may then be attributable to other suppressive factors present in
the hostile tumor environment, such as other regulatory T cell
populations, myeloid-derived suppressor cells, or anti-inflamma-
tory cytokines, which may act directly or indirectly on DC in
tumor and/or draining LN. Indeed, a recent study by Herber et al
[13] showed that DC in tumor bearing hosts upregulate the
scavenger receptor A resulting in increased lipid uptake, and
impaired antigen presenting function.
In conclusion, we show that CD4
+CD25
+ Treg appear to have
little effect on the number, phenotype and function of TIDC in
B16 melanoma, suggesting that the delayed tumor growth
observed in Treg-depleted mice is unlikely to be due to improved
DC function. The question of whether or not Treg affect DC in a
tumor model is complex and highly relevant to designing
improved therapeutic anti-tumor vaccines. This study suggests
that, in order to be optimally effective, regulatory T cell depletion
should be used in association with other forms of immunotherapy
Supporting Information
Figure S1 Identification of Treg in the blood of untreat-
ed and PC61 treated mice. Foxp3GFP mice were treated with
PC61 or left untreated, and injected with B16.OVA tumors s.c. (A)T he
frequencies of Treg in blood from non-depleted mice, or mice depleted
of Treg by PC61 treatment, were determined by flow cytometry. The
lower panels show the Foxp3GFP
+ populations as identified in the top
panels. Each panel refers to an individual representative mouse.
(B) Mice were treated with PC61 or left untreated, and tail bled over
time to monitor the frequency of Tregs in blood by flow cytometry.
CD25
+Foxp3
+ cells were gated as shown in the lower part of panel A.
Average 6 SEM for groups of 5 mice are shown.
(EPS)
Figure S2 TIDC frequency and phenotype are similar in
C57BL/6 and RAG1
2/2 mice. C57BL/6 and RAG1
2/2 mice
were injected with B16.OVA tumors s.c. Tumors were removed 17
days later and analyzed by flow cytometry. (A) Frequencies of
CD11c
hi TIDC in tumors were compared between C57BL/6 and
RAG1
2/2 mice. p was calculated using the Student’s one tailed t test.
(B)Frequenciesof TIDCexpressingthe indicated maturation markers
were compared between C57BL/6 and RAG1
2/2 mice. Values of p
were calculated using a two-way ANOVA test with a Bonferroni post-
test. Data is from one experiment with 9–10 mice per group.
(EPS)
Figure S3 Frequencies of Foxp3
+ T cells in naı ¨ve OTI
and OTII cell populations before transfer into RAG1
2/2
hosts. (A) Frequencies of CD8
+ T cells (top panels) and Foxp3
+
Treg (lower panels) in the total OTI lymphocyte population were
determined before and after enrichment for CD8
+ cells.
(B) Frequencies of CD4
+ T cells (top panels) and Foxp3
+ Treg
(lower panels) in the total OTII lymphocyte population were
determined before and after the cells were depleted of CD25
+ cells
and enriched for CD4
+ cells. The frequency of OVA-specific
(Valpha2
+, Vbeta5.1,5.2
+) Foxp3
+ Treg in the CD4-enriched
population is shown in the right lower panel. Foxp3 expression was
determined by intracellular staining.
(EPS)
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